NASDAQ$LGND
Ligand Pharmaceuticals Incorporated · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2021 and provided an operating forecast and program updates.
Ligand Pharmaceuticals reported excellent third quarter financial results, with total revenues of $64.8 million compared to $41.8 million for the same period in 2020. The company's core royalties tied to Kyprolis and Evomela continue to grow, and they have seen five approvals during the last year for new products or major markets that are now launching and are expected to fuel royalty growth next year and beyond.
- Total revenues for Q3 2021 were $64.8 million, compared to $41.8 million for the same period in 2020.
- Royalties for Q3 2021 were $15.6 million, compared to $9.0 million for the same period in 2020.
- Captisol sales were $35.1 million for Q3 2021, compared to $23.4 million for the same period in 2020, primarily due to higher sales of Captisol for use with remdesivir.
- Net income for Q3 2021 was $13.7 million, or $0.80 per diluted share, compared with net loss of $(6.7) million, or $(0.42) per share, for the same period in 2020.
Headline financials
Revenue & EPS history
Ligand · Revenue · Quarterly
$64.8M
Revenue by segment
Ligand · $50.7M total across 2 segments · Q3 2021
- Captisol Sales$35.1M+50.0%69.2%
- Royalties$15.6M+73.8%30.8%
Forward guidance
Ligand is reaffirming 2021 financial guidance.
Tailwinds
- Full-year 2021 total revenues to be between $265 million and $275 million
- Adjusted earnings per diluted share to be between $5.80 and $6.05
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+0.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+18.7%
Q4 2013
Best reaction
-21.6%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +5.0% | — | |
| Q4 2025 | +2.6% | +6.7% | +2.1% | |
| Q3 2025 | +9.3% | +9.6% | -2.9% | |
| Q1 2025 | -3.2% | +0.0% | +0.4% | |
| Q4 2024 | +0.6% | +0.2% | -6.4% | |
| Q3 2024 | +3.7% | +3.3% | +6.8% | |
| Q2 2024 | -4.9% | +2.1% | +5.1% | |
| Q1 2024 | +10.3% | +19.8% | +13.1% | |
| Q4 2023 | +13.3% | +5.8% | -1.8% | |
| Q3 2023 | +2.8% | +3.8% | +16.3% | |
| Q2 2023 | +6.7% | +1.4% | -4.2% | |
| Q1 2023 | +5.2% | +3.2% | -0.2% | |
| Q4 2022 | +5.9% | +3.0% | -2.1% | |
| Q3 2022 | +12.8% | +31.3% | +6.0% | |
| Q2 2022 | +5.7% | +9.5% | -3.5% | |
| Q1 2022 | -2.9% | -13.0% | -9.1% | |
| Q4 2021 | -16.3% | -19.7% | -8.7% | |
| Q3 2021 | +7.8% | +4.9% | -6.9% | |
| Q2 2021 | -8.1% | -10.0% | -7.4% | |
| Q1 2021 | -9.5% | -10.5% | -22.3% | |
| Q4 2020 | +1.7% | +17.6% | -18.5% | |
| Q3 2020 | -0.2% | +5.4% | +3.4% | |
| Q2 2020 | +0.6% | +0.4% | -11.9% | |
| Q1 2020 | +3.2% | +6.8% | +22.1% | |
| Q4 2019 | +3.3% | +2.8% | +16.7% | |
| Q3 2019 | -7.4% | -1.4% | -4.9% | |
| Q2 2019 | -14.8% | -11.5% | -14.7% | |
| Q1 2019 | -3.3% | -4.1% | -14.6% | |
| Q4 2018 | -2.7% | +1.8% | -10.0% | |
| Q3 2018 | -2.7% | -8.9% | -10.7% | |
| Q2 2018 | +9.8% | +7.7% | +13.0% | |
| Q1 2018 | +7.3% | +13.2% | +26.4% | |
| Q4 2017 | +0.0% | -1.9% | +3.7% | |
| Q3 2017 | -4.9% | -1.3% | -8.4% | |
| Q2 2017 | +5.7% | +2.5% | +9.4% | |
| Q1 2017 | -2.9% | +0.2% | +1.2% | |
| Q4 2016 | -2.8% | +1.3% | +1.5% | |
| Q3 2016 | -2.7% | +3.1% | +10.8% | |
| Q2 2016 | -7.4% | -13.2% | -20.2% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +5.1% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +4.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | +18.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q1 2013 | +1.7% | — | — | |
| Q4 2012 | +7.4% | — | — | |
| Q3 2012 | +10.8% | — | — | |
| Q2 2012 | -8.8% | — | — | |
| Q4 2011 | -8.8% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q3 2011 | -21.6% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | -2.4% | — | — | |
| Q2 2010 | -3.6% | — | — | |
| Q1 2010 | -9.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro